❌

Normal view

  • ✇STAT
  • Coroner releases details of infants who died amid growing Pennsylvania measles outbreak Associated Press
    NEW YORK — The two measles-related deaths in Pennsylvania last month involved infants, and the virus itself caused one of the deaths, a Pennsylvania coroner confirmed Wednesday. Lancaster County’s coroner, Dr. Stephen Diamantoni, said he told the Centers for Disease Control and Prevention of his conclusions. CDC officials, however, have not said whether they will count either death as measles-associated, and the agency’s website still carries a disclaimer about them.Read the rest…
     

Coroner releases details of infants who died amid growing Pennsylvania measles outbreak

10 September 2026 at 05:44

NEW YORK — The two measles-related deaths in Pennsylvania last month involved infants, and the virus itself caused one of the deaths, a Pennsylvania coroner confirmed Wednesday.

Lancaster County’s coroner, Dr. Stephen Diamantoni, said he told the Centers for Disease Control and Prevention of his conclusions. CDC officials, however, have not said whether they will count either death as measles-associated, and the agency’s website still carries a disclaimer about them.

Read the rest…

© Cynthia Goldsmith/Centers for Disease Control and Prevention, via AP

  • ✇STAT
  • Telemedicine company offers GLP-1s for addiction Theresa Gaffney and Helen Branswell
    Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. I didn’t have space to mention it yesterday, but can you believe Nathan Fielder made an Elizabeth Holmes documentary? Variety called it shameless and fascinating. I may need to see for myself. Read the rest…
     

Telemedicine company offers GLP-1s for addiction

9 September 2026 at 19:53

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Good morning. I didn’t have space to mention it yesterday, but can you believe Nathan Fielder made an Elizabeth Holmes documentary? Variety called it shameless and fascinating. I may need to see for myself. 

Read the rest…

© Adobe

  • ✇STAT
  • STAT+: FDA warns an API supplier about residue on walls, a corroded product line, and open-toed sandals Ed Silverman
    Residue and stains plastered on production walls, floors, and manufacturing equipment. Corrosion on a product line. An employee wearing open-toed sandals. These were among the unsanitary conditions found last April by a Food and Drug Administration inspector during a visit to Shoolin Pharma in Gujarat, India, where the company makes active pharmaceutical ingredients for more than a dozen medicines, including erectile dysfunction and anti-convulsant pills, that are sold to compounding pharmaci
     

STAT+: FDA warns an API supplier about residue on walls, a corroded product line, and open-toed sandals

9 September 2026 at 01:38

Residue and stains plastered on production walls, floors, and manufacturing equipment. Corrosion on a product line. An employee wearing open-toed sandals.

These were among the unsanitary conditions found last April by a Food and Drug Administration inspector during a visit to Shoolin Pharma in Gujarat, India, where the company makes active pharmaceutical ingredients for more than a dozen medicines, including erectile dysfunction and anti-convulsant pills, that are sold to compounding pharmacies in the U.S., according to the agency.

The concerns about filth and possible contamination in the production and packaging areas — as well as incomplete laboratory testing records — prompted the agency last month to halt all product shipments by the company into the U.S., the FDA disclosed in an Aug. 18 warning letter that was posted on the FDA web site last week.

Continue to STAT+ to read the full story…

© Adobe

  • ✇STAT
  • STAT+: Health care features prominently in Democrats’ agenda John Wilkerson
    You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. House Republicans canceled the last two weeks of their session in September, which means House lawmakers will have gotten at least 15 weeks off between Memorial Day and the midterms on Nov. 3. Send news tips and PTO requests to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal. Hou
     

STAT+: Health care features prominently in Democrats’ agenda

8 September 2026 at 22:22

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

House Republicans canceled the last two weeks of their session in September, which means House lawmakers will have gotten at least 15 weeks off between Memorial Day and the midterms on Nov. 3. Send news tips and PTO requests to John.Wilkerson@statnews.com or John_Wilkerson.07 on Signal.

House Democrats’ agenda takes shape

In the week that the House was in town, a fuzzy outline of the health care agenda that Democrats are considering should they win back the House started to take form.

Continue to STAT+ to read the full story…

© Tasos Katopodis/Getty Images for DNC

  • ✇STAT
  • An administrative gap delays access to new pancreatic cancer treatment  Theresa Gaffney
    Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. An exciting post-Labor Day announcement: While STAT’s Lev Facher is away on a Knight-Wallace Fellowship, I’ll be covering the addiction beat for him! My first story published last week. Send me news tips and story ideas to tackle over the next eight months: theresa.gaffney@statnews.com Read the rest…
     

An administrative gap delays access to new pancreatic cancer treatment 

8 September 2026 at 19:32

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Good morning. An exciting post-Labor Day announcement: While STAT’s Lev Facher is away on a Knight-Wallace Fellowship, I’ll be covering the addiction beat for him! My first story published last week. Send me news tips and story ideas to tackle over the next eight months: theresa.gaffney@statnews.com 

Read the rest…

© Revolution Medicines

  • ✇MIT Technology Review
  • This geneticist’s age-reversal tech could help restore sight Antonio Regalado
    Yuancheng (Ryan) Lu is obsessed with aging. And with eyes. As he steps outside the Whitehead Institute in Cambridge, Massachusetts, his aviator glasses darken automatically in the sun. Age-related blindness runs in his family. A great-aunt in China, the story goes, was killed crossing a road because she couldn’t see oncoming traffic. And Lu’s own 23andMe test came back with a mutation for macular degeneration, a top cause of vision loss in old age. Exposure to bright sunlight is another risk fac
     

This geneticist’s age-reversal tech could help restore sight

8 September 2026 at 18:32

Yuancheng (Ryan) Lu is obsessed with aging. And with eyes. As he steps outside the Whitehead Institute in Cambridge, Massachusetts, his aviator glasses darken automatically in the sun. Age-related blindness runs in his family. A great-aunt in China, the story goes, was killed crossing a road because she couldn’t see oncoming traffic. And Lu’s own 23andMe test came back with a mutation for macular degeneration, a top cause of vision loss in old age. Exposure to bright sunlight is another risk factor—thus the shades. “They protect me,” he says. “Plus, they look cool.”

Lu, 34, works on gene therapies to prevent age-related vision loss. “I think the eye is a really unique system to study aging and rejuvenation,” he says. “I could give a whole presentation.” Pushing up my reading glasses, I lean in to listen.

Lu is behind one of the coolest results in rejuvenation science—and in eye research. In 2018, while earning his PhD at Harvard Medical School, he used an age-reversal technique called reprogramming to repair the optic nerves of mice. He crushed the nerves, blinding the animals, and then injected the cells with a gene therapy meant to restore them to a youthful state. Sixteen days later, the nerves were growing back, their axons showing up through a microscope as spidery orange filaments.

As hype around age reversal swirls, Lu has been busy in the lab searching for what he calls “the next generation of rejuvenation therapies.”

The head of that lab, the longevity scientist David Sinclair, remembers when Lu texted him the pictures: “He asked me, ‘What do you see here?’ And I said, ‘I see the future.’” Later tests carried out in a box with rotating bars of light showed the mice were tracking the changes. They could see again.

This year, nearly the exact genetic therapy Lu created for mice entered human clinical trials. On June 9, the startup Life Biosciences, which Sinclair cofounded and in which Lu owns a small stake, announced it had injected the treatment into the eye of a person with glaucoma. The trial has been big news. A headline in the New York Times suggested the technology could “change humanity.” Posters on X gushed, with one declaring that “the fountain of youth is here.”

“It’s remarkable that what he developed as a student is now going into humans,” says Sinclair of the treatment, now called ER-100. “It’s barely even changed since he built it.”

Reprogramming refers to an age-­restoring process that takes place inside an embryo. It’s why babies are born young, not old: The DNA they’ve inherited from their parents has been scrubbed and reset. In 2006, Japanese researchers showed they could cause the process to occur in the lab by introducing just four key genes, known by the acronym OSKM. Add these to a cell from a 100-year-old and it will turn into a stem cell that acts as if it was plucked from an embryo.

That’s powerful stuff. But we don’t want to turn people into blobs of stem-cell protoplasm. Lu figured out a way to control the effect. He trimmed the list of genes to just OSK—leaving out M, for Myc, the one most likely to cause dangerous changes like cancer. His extra flash of insight was that reprogramming could be tested on the optic nerve; the eye is particularly accessible.

Lu’s result, published in Nature in 2020, helped set off an investment rush. Since then, US tech billionaires have placed huge bets on private companies like Altos Labs and NewLimit to explore reprogramming and anti-aging medicine. The day I spoke with Lu, he’d spent the morning meeting with the business magnate Zhong Shanshan, one of China’s richest people.  

Still, as hype around age reversal swirls, Lu has been notably absent from the public conversation. He’s been busy in the lab searching for what he calls “the next generation of rejuvenation therapies.” With a sigh, Lu describes the grueling effort over the last six years to understand what OSK really does. The treatment remains toxic to many cell types, and he says it’s becoming obvious that different factors drive aging in each kind. This year, for example, he identified a gene responsible for protecting the retina from damage by free radicals—the main cause of age-­related macular degeneration.

While Sinclair, his former boss, believes humans could live to be 200, Lu disagrees. There’s just too much that goes wrong as we age. His work with OSK, he says, was more a proof of concept than a silver bullet. But it did change the conversation. “Six years ago, you couldn’t talk about rejuvenation. We didn’t use that word—there was pushback,” Lu tells me. “But I think people have accepted the concept that you can really reverse molecular age.” 

  • ✇STAT
  • Trump wraps up three-hour medical visit to Walter Reed and declares ‘Everything checked out PERFECTLY’ Associated Press
    WASHINGTON — President Donald Trump had another medical exam on Tuesday, putting his health under renewed public scrutiny as he has worked to dismiss concerns over his age and stamina. The 79-year-old president spent more than three hours at Walter Reed National Military Medical Center for what the White House described as preventive medical and dental checkups. It was Trump’s fourth publicly disclosed medical exam since he returned to office for a second term, and it comes as he tries to pro
     

Trump wraps up three-hour medical visit to Walter Reed and declares ‘Everything checked out PERFECTLY’

26 May 2026 at 22:32

WASHINGTON — President Donald Trump had another medical exam on Tuesday, putting his health under renewed public scrutiny as he has worked to dismiss concerns over his age and stamina.

The 79-year-old president spent more than three hours at Walter Reed National Military Medical Center for what the White House described as preventive medical and dental checkups. It was Trump’s fourth publicly disclosed medical exam since he returned to office for a second term, and it comes as he tries to project strength ahead of midterm elections that will test his sway with voters.

Read the rest…

© Manuel Balce Ceneta/AP

TechCrunch Disrupt 2026 Early Bird ticket rates end May 29

26 May 2026 at 22:00
Save up to $410 on your TechCrunch Disrupt 2026 pass before prices increase on May 29 at 11:59 p.m. PT. Register here to join the tech epicenter in San Francisco.

Ebola outbreak continues to worsen, with new collateral risks for girls and women

26 May 2026 at 21:13

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Good morning. Here’s the news you need to know after the long weekend. 

Read the rest…

© OLIVIER DOULIERY/AFP via Getty Images

  • ✇STAT
  • STAT+: Eli Lilly to buy three small vaccine developers Andrew Joseph
    Eli Lilly said Tuesday it would buy three early- and mid-stage vaccine developers, a boost for the field.  The deals — which together could cost up to nearly $4 billion — are the latest acquisitions from Lilly, a company rich with cash from its booming GLP-1 business. In recent months, it’s picked up companies working on cancer, autoimmune diseases, and sleep disorders, all for under $10 billion each.  The companies being bought are Curevo, LimmaTech Biologics, and Vaccine Company. Continu
     

STAT+: Eli Lilly to buy three small vaccine developers

26 May 2026 at 19:29

Eli Lilly said Tuesday it would buy three early- and mid-stage vaccine developers, a boost for the field. 

The deals — which together could cost up to nearly $4 billion — are the latest acquisitions from Lilly, a company rich with cash from its booming GLP-1 business. In recent months, it’s picked up companies working on cancer, autoimmune diseases, and sleep disorders, all for under $10 billion each. 

The companies being bought are Curevo, LimmaTech Biologics, and Vaccine Company. 

Continue to STAT+ to read the full story…

© Craig F. Walker/Globe Staff

  • ✇STAT
  • Opinion: The Ebola outbreak will lead to devastating violence against women and girls Lindsay Stark and Ilana Seff
    The World Health Organization has declared a new public health emergency. Bundibugyo, an Ebola strain for which we have no vaccine and no treatment, is now spreading across the eastern Democratic Republic of Congo. So far, there have been more than 900 suspected cases and about 220 suspected deaths, according to the World Health Organization. Centered in a region with active conflict and fragile health systems, the outbreak has already crossed the borders into Uganda. Public health advocates
     

Opinion: The Ebola outbreak will lead to devastating violence against women and girls

26 May 2026 at 16:30

The World Health Organization has declared a new public health emergency. Bundibugyo, an Ebola strain for which we have no vaccine and no treatment, is now spreading across the eastern Democratic Republic of Congo. So far, there have been more than 900 suspected cases and about 220 suspected deaths, according to the World Health Organization. Centered in a region with active conflict and fragile health systems, the outbreak has already crossed the borders into Uganda.

Public health advocates will spend the next several months talking about transmission, case fatality, contact tracing, and vaccine development. But one critical topic will go largely undiscussed: what this outbreak will do to women and girls.

Read the rest…

© ALEXIS HUGUET/AFP via Getty Images

Opinion: 8 former CDC directors: Reform PEPFAR, don’t dismantle it

On Sunday, the World Health Organization (WHO) declared an Ebola outbreak in the Democratic Republic of the Congo and Uganda to be a public health emergency. This outbreak is deadly, with hundreds of cases across at least two countries, including, by report, one American who was working in the area.

At the same time, a cluster of hantavirus cases linked to a Dutch cruise ship in the South Atlantic has killed three and exposed hundreds more.

Read the rest…

© Hajarah Nalwadda/Getty Images

  • ✇STAT
  • Opinion: How the perimenopause movement is hurting women Torie Bosch
    Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Patricia Bencivenga and Adriane Fugh-Berman. Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday. Torie Bosch: Brain fog and weight gain and hair lo
     

Opinion: How the perimenopause movement is hurting women

23 May 2026 at 19:00

Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Patricia Bencivenga and Adriane Fugh-Berman. Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, or wherever you get your podcasts. Get alerts about each new episode by signing up for the “First Opinion Podcast” newsletter. And don’t forget to sign up for the First Opinion newsletter, delivered every Sunday.

Torie Bosch: Brain fog and weight gain and hair loss and insomnia — those are the calling cards of perimenopause. At least that’s what the new perimenopause awareness movement claims. But what’s real and what’s just social media misinformation?

Read the rest…

  • ✇STAT
  • STAT+: Congress slashed Medicaid funding to providers. The Trump administration wants to cut even further Tara Bannow
    Hospitals and other providers are bracing for an end to the extra money they’ve gotten for treating Medicaid patients, one of the many cuts contained in Republicans’ sweeping 2025 tax law. But the Trump administration disclosed this week that it plans to take the cuts to state directed payments even further, setting up what’s likely to be a showdown with provider groups.  Since 2024, some hospitals, doctors, nursing homes, and other types of providers have been reimbursed for Medicaid serv
     

STAT+: Congress slashed Medicaid funding to providers. The Trump administration wants to cut even further

23 May 2026 at 01:19

Hospitals and other providers are bracing for an end to the extra money they’ve gotten for treating Medicaid patients, one of the many cuts contained in Republicans’ sweeping 2025 tax law.

But the Trump administration disclosed this week that it plans to take the cuts to state directed payments even further, setting up what’s likely to be a showdown with provider groups. 

Since 2024, some hospitals, doctors, nursing homes, and other types of providers have been reimbursed for Medicaid services at much higher commercial rates, thanks to a Biden-era change. The One Big Beautiful Bill Act, passed in July, directs the Centers for Medicare and Medicaid Services to gradually trim those payments beginning in 2028 until they’re close to or on par with Medicare rates. 

Continue to STAT+ to read the full story…

© Chip Somodevilla/Getty Images

  • ✇STAT
  • A CDC page on mpox caught in political crosshairs Theresa Gaffney
    Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning and happy Friday. I hope you’ve got great long weekend plans ahead. But first, scroll down to read about a Senate hearing on the NIH, a Supreme Court death penalty decision, and two related items on confusion around STIs. Read the rest…
     

A CDC page on mpox caught in political crosshairs

22 May 2026 at 21:14

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Good morning and happy Friday. I hope you’ve got great long weekend plans ahead. But first, scroll down to read about a Senate hearing on the NIH, a Supreme Court death penalty decision, and two related items on confusion around STIs. 

Read the rest…

© Adobe

  • ✇MIT Technology Review
  • The Enhanced Games fit right in with the rest of 2026’s longevity vibes Jessica Hamzelou
    This Sunday, a group of 42 athletes will gather in Las Vegas to compete in a somewhat unusual sporting competition. Participants in the inaugural Enhanced Games are being encouraged to take performance-enhancing drugs. The goal is to “push the boundaries of human performance.” The games’ organizers have said that competitors will only be taking substances that have been approved by the US Food and Drug Administration, and that they are all being medically monitored and supervised. But they
     

The Enhanced Games fit right in with the rest of 2026’s longevity vibes

22 May 2026 at 17:00

This Sunday, a group of 42 athletes will gather in Las Vegas to compete in a somewhat unusual sporting competition. Participants in the inaugural Enhanced Games are being encouraged to take performance-enhancing drugs. The goal is to “push the boundaries of human performance.”

The games’ organizers have said that competitors will only be taking substances that have been approved by the US Food and Drug Administration, and that they are all being medically monitored and supervised. But they have also said they expect to see world records broken—and are offering substantial prizes to athletes who succeed in doing so.

As you might expect, the event is generating a mix of curiosity, excitement, and condemnation from various quarters. To me, it feels like very much a reflection of where we are today—an era of peptide-crazed looksmaxxing in which consumers are being encouraged to get thinner than ever, optimize for longevity, and have their “best baby.” It’s 2026, and if you’re not enhancing, what are you even doing?

So, these games. They’ll feature competitions in four categories: swimming, track and field, weightlifting, and strongman (which also involves lifting weights). Many of the competitors already hold national and world records, and some are Olympic medalists. They’ve been paid a salary and will compete for prizes from a $25 million pot. The money has been a major draw for at least some of the athletes.

Another draw is the opportunity to openly experiment with drugs that might boost their performance. In the world of elite sport, every microsecond and every millimeter counts. Athletes—most of whom arguably have genetics on their side already—follow meticulous diet, training, and recovery protocols and wear specially designed gear that allows them to reach for those performance bests.

But within most sporting communities, there are limits. The World Anti-Doping Agency—an international outfit that fights the use of drugs in sports—maintains a lengthy list of “non-approved substances” that are banned in international sporting events. It features many anabolic steroids (which can build muscle), hormones (such as those that stimulate testosterone production or increase the ability of blood to carry oxygen), growth factors (which can stimulate muscle growth and repair, among other things), and more.

Some of these substances have been FDA approved to treat health disorders. And that means they can be used by participants in the Enhanced Games, according to the organization’s rules.

I’ll briefly point out the obvious here—just because a drug has been approved by the FDA doesn’t mean it’s totally safe for everyone and anyone. The risks associated with use of anabolic steroids, for example, include high blood pressure, acne, depression, and liver tumors. Growth hormone use can cause weak muscles, affect vision, and even lead to diabetes.

“Technological doping,” or using improved equipment to gain advantage, has also been supported by the games’ organizers. Last year, participating swimmer Kristian Gkolomeev was reported to have broken a record in a 50-meter freestyle time trial while wearing a polyurethane “super” swimsuit. Such suits have been banned for use in the Olympics since a slew of record-breaking performances in 2008 and 2009. Back then, the swimming governing body ruled that they gave athletes an unfair advantage. But hey, this is the Enhanced Games, where the word “unfair” seems to have a completely different meaning.

Can we expect more records to be broken on Sunday? Maybe. In addition to prize money for winning an event, any athlete who manages to beat a record stands to win up to $1 million, the sum also awarded to Gkolomeev last year following his time trial. But those performances won’t be recognized by official sporting bodies.

Plenty of concerns have been raised about these games. Some argue that they are unsafe and promote risky drug use. Others see them as a “clown show,” and a slap in the face to “clean” athletes who train hard without the use of prohibited drugs. World Athletics president Sebastian Coe has said that anyone who takes part is “moronic,” and World Aquatics, which oversees international competitions in water sports, has banned Enhanced Games participants from its events and activities.

But. The games—and the participating athletes—will still get a huge amount of attention. As a result, so will performance-enhancing drugs. Enhanced, the company behind the games, also runs an online store. There, you can buy a $52 T-shirt emblazoned with the message “I am Enhanced.”

There is also a range of prescription drugs on offer, including peptides “to support recovery, vitality, and longevity.” One of these is a growth hormone that the FDA approved in 1997 for the treatment of children with “growth failure.” The compounded version offered on the Enhanced website, which is not FDA approved, is marketed for longevity, supporting deep sleep and “overall wellness and vitality.” (“Marketed” is the key word here. The drug has, again, not been approved for that purpose.)

It all fits very well with the zeitgeist. Sure, we don’t yet have any drugs that are designed to extend human lifespan. But the search for anti-aging drugs is getting more attention—and funding—than ever. People, particularly women, are seemingly not allowed to visibly age anymore—we have filters and facelifts for that now. The idea that “death is wrong” is gaining acceptance.

And self-experimentation is rife. “Biohacking” was shortlisted for Collins Dictionary’s Word of the Year in 2025. Peptides are everywhere, despite all the unknowns surrounding their safety and effectiveness. So are longevity clinics, despite the fact that most are selling unproven treatments. US states like Montana are making it easier for people to get hold of unapproved “therapies.”

Companies are even offering would-be parents the option to choose the potential future children expected to live longest. Yep—you can supposedly optimize your embryos now, too.

In this climate, the Enhanced Games don’t feel so radical. They feel entirely fitting for our era of questionable optimization despite the risks —an era when, apparently, being human is no longer enough.

  • ✇STAT
  • GAO report shows gap between scale of illegal vapes and enforcement  Sarah Todd
    With thousands of illegal e-cigarettes for sale in the U.S., both the Trump and Biden administrations have vowed to crack down on the illicit fruit- and candy-flavored vapes that hold particular appeal to minors. But a new government report suggests law enforcement efforts by the Department of Justice lag far behind the scope of the problem.  Most DOJ enforcement actions between fiscal year 2022 and fiscal year 2025 — 50 out of a total of 88 — were to add the names of remote e-cigarette selle
     

GAO report shows gap between scale of illegal vapes and enforcement 

11 April 2026 at 00:00

With thousands of illegal e-cigarettes for sale in the U.S., both the Trump and Biden administrations have vowed to crack down on the illicit fruit- and candy-flavored vapes that hold particular appeal to minors. But a new government report suggests law enforcement efforts by the Department of Justice lag far behind the scope of the problem. 

Most DOJ enforcement actions between fiscal year 2022 and fiscal year 2025 — 50 out of a total of 88 — were to add the names of remote e-cigarette sellers to a list of unauthorized businesses, according to the report from the Government Accountability Office. The second-most common type of enforcement actions (20 out of 88) noted in the report were injunctions to stop legal violations. 

Read the rest…

© Stephanie Keith/Getty Images

  • ✇MIT Technology Review
  • What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma Antonio Regalado
    Is it the Department of Defense or the Department of War? The Gulf of Mexico or the Gulf of America? A vaccine—or an “individualized neoantigen treatment”? That’s the Trump-era vocabulary paradox facing Moderna, the covid-19 shot maker whose plans for next-generation mRNA vaccines against flus and emerging pathogens have been dashed by vaccine skeptics in the federal government. Canceled contracts and unfriendly regulators have pushed the Massachusetts-based biotech firm to a breaking point.
     

What’s in a name? Moderna’s “vaccine” vs. “therapy” dilemma

10 April 2026 at 22:04

Is it the Department of Defense or the Department of War? The Gulf of Mexico or the Gulf of America? A vaccine—or an “individualized neoantigen treatment”?

That’s the Trump-era vocabulary paradox facing Moderna, the covid-19 shot maker whose plans for next-generation mRNA vaccines against flus and emerging pathogens have been dashed by vaccine skeptics in the federal government. Canceled contracts and unfriendly regulators have pushed the Massachusetts-based biotech firm to a breaking point. Last year, Robert F. Kennedy Jr., head of the Department of Health and Human Services, zeroed in on mRNA, unwinding support for dozens of projects—including a $776 million award to Moderna for a bird flu vaccine. By January, the company was warning it might have to stop late-stage programs to develop vaccines against infections altogether.

That raises the stakes for a second area of Moderna’s research. In a partnership with Merck, it’s been using its mRNA technology to destroy tumors through a very, very promising technique known as a cancer vacc—

“It’s not a vaccine,” a spokesperson for Merck jumped in before the V-word could leave my mouth. “It’s an individualized neoantigen therapy.”

Oh, but it is a vaccine. And here’s how it works. Moderna sequences a patient’s cancer cells to find the ugliest, most peculiar molecules on their surface. Then it packages the genetic code for those same molecules, called neoantigens, into a shot. The patient’s immune system has its orders: Kill any cells with those yucky surface markers.

Mechanistically, it’s similar to the covid-19 vaccines. What’s different, of course, is that the patient is being immunized against a cancer, not a virus.

And it looks like a possible breakthrough. This year, Moderna and Merck showed that such shots halved the chance that patients with the deadliest form of skin cancer would die from a recurrence after surgery.

In its formal communications, like regulatory filings, Moderna hasn’t called the shot a cancer vaccine since 2023. That’s when it partnered up with Merck and rebranded the tech as individualized neoantigen therapy, or INT. Moderna’s CEO said at the time that the renaming was to “better describe the goal of the program.” (BioNTech, the European vaccine maker that’s also working in cancer, has shifted its language too, moving from “neoantigen vaccine” in 2021 to “mRNA cancer immunotherapies” in its latest report.)

The logic of casting it as a therapy is that patients already have cancer—so it’s a treatment as opposed to a preventive measure. But it’s no secret what the other goal is: to distance important innovation from vaccine fearmongering, which has been inflamed by high-ranking US officials. “Vaccines are maybe a dirty word nowadays, but we still believe in the science and harnessing our immune system to not only fight infections, but hopefully to also fight … cancers,” Kyle Holen, head of Moderna’s cancer program, said last summer during BIO 2025, a big biotech event in Boston.

Not everyone is happy with the word games. Take Ryan Sullivan, a physician at Massachusetts General Hospital who has enrolled patients in Moderna’s trials. He says the change raises questions over whether trial volunteers are being properly informed. “There is some concern that there will be patients who decline to treat their cancer because it is a vaccine,” Sullivan told me. “But I also felt it was important, as many of my colleagues did, that you have to call it what it is.”

But is it worth going to the mat for a word? Lillian Siu, a medical oncologist at the Princess Margaret Cancer Centre, in Toronto, who has played a role in safety testing for the new shots, watches US politics from a distance. She believes name change is acceptable “if it allows the research to continue.”

Holen told me the doctors complaining to Moderna were basically motivated by a desire to defend vaccines—which are, of course, among the greatest public health interventions of all time. They wanted the company to stand strong. 

But that’s not what’s happening. When Moderna’s latest results were published in February, the paper’s main text didn’t use the word “vaccine” at all. It was only in the footnotes that you could see the term—in the titles of old papers and patents.

All this could be a sign that Kennedy’s strategy is working. His agencies often appear to make mRNA vaccines a focus of people’s worries, impede their reach, devalue them for companies, and sideline their defenders. 

Still, Moderna’s strategy may be working too. So far, at least, the government hasn’t had much to say about the company’s cancer vacc— I mean, its individualized neoantigen therapy.

This article first appeared in The Checkup, MIT Technology Review’s weekly biotech newsletter. To receive it in your inbox every Thursday, and read articles like this first, sign up here.

  • ✇STAT
  • STAT+: GSK says goodbye to leucovorin (again) O. Rose Broderick
    Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Buyer beware: If you are an avid consumer of WAP Sensual Enhancement, the Food and Drug Administration says the pill “may be harmful.” Want to learn about other dubious products under federal scrutiny? Scroll down.Continue to STAT+ to read the full story…
     

STAT+: GSK says goodbye to leucovorin (again)

10 April 2026 at 21:02

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Buyer beware: If you are an avid consumer of WAP Sensual Enhancement, the Food and Drug Administration says the pill “may be harmful.”

Want to learn about other dubious products under federal scrutiny? Scroll down.

Continue to STAT+ to read the full story…

© JUSTIN TALLIS/AFP via Getty Images

❌